Targeted metabolomics studies have further confirmed that disruptions in sphingolipid metabolism are closely associated with the biological changes observed in the preclinical and prodromal stages of AD, particularly in relation to Tau phosphorylation, Aβ metabolism, and apoptosis (Varma et al., 2018). Here, MAPT is linked to Alzheimer disease.